Main Article Content


Morinda reticulate has been traditionally used for many ailments. In the present study, anti-cancer activity of methanolic extract of Morinda reticulate (MEMR) was evaluated using both in-vitro and in-vivo methods. METS was subjected to preliminary qualitative phytochemical investigations by using standard procedures. In-vitro antitumor activity of MEMR was evaluated by the MTT assay method using Vero and HEP‐2 cell lines. Then the extract subjected to in vivo anti-cancer activity using Ehrlich ascites carcinoma (EAC) tumor model. The activity was assessed Increase in life span, average increase in body weight, and changes in food intake, tumor volume, tumor weight, viable cell count, non-viable cell count, PCV, Total cell count and hematological studies. The characterization of the active constituents was performed using column chromatography, PTLC & IR. The potency of the extract was compared with standard 5-flurouracil (20 mg/kg i.p.). In in vitro anti-cancer activity MEMR exhibited significant cytotoxic activity against both cell lines even at different concentrations. Oral administration of MEMR at the dose of 200 and 400 mg/Kg, significantly (p < 0.001) increased the survival time, non-viable cell count and decreased the average body weight and food intake, viable cell count of the tumor bearing mice. After 14 days of inoculation, MEMR was able to reverse the changes in the hematological parameters, protein and PCV consequent to tumor inoculation. Based on the analytical data the compound- I & II was found to be Phyto sterol. The results indicate that MEMR possess significant antitumor activity on dose dependent manner.


Morinda reticulate Ehrlich Ascites Carcinoma Hematological Parameters PCV survival time.

Article Details